{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:05:06Z","timestamp":1781521506639,"version":"3.54.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1053\/j.ackd.2019.08.004","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T19:14:08Z","timestamp":1583435648000},"page":"18-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Toxicity of Metformin and Hypoglycemic Therapies"],"prefix":"10.1053","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8369-5084","authenticated-orcid":false,"given":"Muhammad S.","family":"Akhter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2364-0559","authenticated-orcid":false,"given":"Priyasha","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.ackd.2019.08.004_bib1","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"issue":"Suppl. 1","key":"10.1053\/j.ackd.2019.08.004_bib3","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"Oct","key":"10.1053\/j.ackd.2019.08.004_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.biopha.2018.07.085","article-title":"A preclinical overview of metformin for the treatment of type 2 diabetes","volume":"106","author":"Zhou","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci"},{"issue":"9131","key":"10.1053\/j.ackd.2019.08.004_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"The Lancet"},{"issue":"15","key":"10.1053\/j.ackd.2019.08.004_bib7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1053\/j.ackd.2019.08.004_bib8","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular outcomes in trials of oral diabetes medications","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.004_bib10","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbadis.2016.09.019","article-title":"Metformin, beyond an insulin sensitizer, targeting heart and pancreatic \u03b2 cells","volume":"1863","author":"Yang","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.004_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diacare.17.10.1100","article-title":"Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study","volume":"17","author":"Hermann","year":"1994","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9343(96)00353-1","article-title":"An overview of metformin in the treatment of type 2 diabetes mellitus","volume":"102","author":"Davidson","year":"1997","journal-title":"Am J Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM","volume":"15","author":"Bailey","year":"1992","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib17","first-page":"233","article-title":"Metformin: a review of its pharmacological properties and therapeutic use","volume":"5","author":"Hermann","year":"1979","journal-title":"Diabete Metab"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib19","first-page":"89","article-title":"Metformin: a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Rev"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1185\/030079904125003278","article-title":"Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study","volume":"20","author":"Blonde","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/14746514040040041101","article-title":"New prolonged-release metformin improves gastrointestinal tolerability","volume":"4","author":"Davidson","year":"2004","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"18","key":"10.1053\/j.ackd.2019.08.004_bib22","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.166.18.1975","article-title":"Risk factors of vitamin B12 deficiency in patients receiving metformin","volume":"166","author":"Ting","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.004_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"New Engl J Med"},{"issue":"6225","key":"10.1053\/j.ackd.2019.08.004_bib24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/bmj.280.6225.1214","article-title":"Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment","volume":"280","author":"Callaghan","year":"1980","journal-title":"BMJ"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.004_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2337\/diacare.23.9.1227","article-title":"Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin","volume":"23","author":"Bauman","year":"2000","journal-title":"Diabetes Care"},{"issue":"may19 4","key":"10.1053\/j.ackd.2019.08.004_bib26","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial","volume":"340","author":"De Jager","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.rce.2019.01.001","article-title":"Metformin-associated lactic acidosis, a ghost or a murderer?","volume":"219","author":"G\u00f3mez-Peralta","year":"2019","journal-title":"Rev Clin Esp"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.004_bib28","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.004_bib29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.004_bib30","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2337\/dc14-0464","article-title":"Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study","volume":"37","author":"Richy","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.003","article-title":"Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","article-title":"Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy","volume":"6","author":"Lachin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"may22 2","key":"10.1053\/j.ackd.2019.08.004_bib33","doi-asserted-by":"crossref","first-page":"b1668","DOI":"10.1136\/bmj.b1668","article-title":"Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance","volume":"338","author":"Adler","year":"2009","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MNH.0000000000000349","article-title":"Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease","volume":"26","author":"Rajani","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1389450118666170601130947","article-title":"AMP-activated protein kinase as a drug target in chronic kidney disease","volume":"19","author":"Allouch","year":"2018","journal-title":"Curr Drug Targets"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jcp.25598","article-title":"Nephroprotective effects of metformin in diabetic nephropathy","volume":"232","author":"Ravindran","year":"2016","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib37","doi-asserted-by":"crossref","first-page":"F226","DOI":"10.1152\/ajprenal.00495.2014","article-title":"Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis","volume":"308","author":"Kim","year":"2015","journal-title":"Am J Physiology-Renal Physiol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40620-015-0258-1","article-title":"Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions","volume":"29","author":"Langer","year":"2016","journal-title":"J Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/1440-1681.12748","article-title":"Metformin attenuates renal fibrosis in both AMPK\u03b12-dependent and independent manners","volume":"44","author":"Feng","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.004_bib40","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1681\/ASN.2018010050","article-title":"Phosphorylation of Acetyl-CoA Carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin","volume":"29","author":"Lee","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"31","key":"10.1053\/j.ackd.2019.08.004_bib41","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.2174\/0929867324666170404143102","article-title":"Update on the protective renal effects of metformin in diabetic nephropathy","volume":"24","author":"Eisenreich","year":"2017","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbadis.2017.10.014","article-title":"Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK","volume":"1864","author":"Rogacka","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","article-title":"Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder","volume":"94","author":"Neven","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1440-1797.2010.01328.x","article-title":"Review: metformin: Potential benefits and use in chronic kidney disease","volume":"15","author":"PILMORE","year":"2010","journal-title":"Nephrology"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib45","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: the safest hypoglycaemic agent in chronic kidney disease?","volume":"118","author":"Nye","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2337\/dc09-1284","article-title":"Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations","volume":"33","author":"Frid","year":"2010","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.004_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0953-6205(02)00131-0","article-title":"Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications","volume":"13","author":"Rachmani","year":"2002","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5694\/j.1326-5377.2008.tb01713.x","article-title":"Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study","volume":"188","author":"Kamber","year":"2008","journal-title":"Med J Aust"},{"key":"10.1053\/j.ackd.2019.08.004_bib49","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib50","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and\u00a0safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mem.2001.114314","article-title":"Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment","volume":"38","author":"Harrigan","year":"2001","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.emc.2007.02.010","article-title":"Emergency management of oral hypoglycemic drug toxicity","volume":"25","author":"Rowden","year":"2007","journal-title":"Emerg Med Clin North Am"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11892-014-0473-5","article-title":"Sulfonylureas: a new look at old therapy","volume":"14","author":"Thul\u00e9","year":"2014","journal-title":"Curr Diab Rep"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.004_bib54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S2213-8587(18)30025-1","article-title":"Do sulphonylureas still have a place in clinical practice?","volume":"6","author":"Khunti","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.me.31.020180.001401","article-title":"Efficacy and safety of oral hypoglycemic agents","volume":"31","author":"Selizer","year":"1980","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1053\/j.ackd.2019.08.004_bib56","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2019.08.004_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.biochi.2017.07.002","article-title":"Misunderstandings and controversies about the insulin-secreting properties of antidiabetic sulfonylureas","volume":"143","author":"Henquin","year":"2017","journal-title":"Biochimie"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1463-1326.2011.01496.x","article-title":"Variations in tissue selectivity amongst insulin secretagogues: a systematic review","volume":"14","author":"Abdelmoneim","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0079-6107(89)90013-8","article-title":"Electrophysiology of the pancreatic \u03b2-cell","volume":"54","author":"Ashcroft","year":"1989","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1053\/j.ackd.2019.08.004_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1463-1326.2011.01507.x","article-title":"Treating diabetes today: a matter of selectivity of sulphonylureas","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib62","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCRESAHA.107.165324","article-title":"The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATPChannel","volume":"102","author":"Burke","year":"2008","journal-title":"Circ Res"},{"issue":"1-2","key":"10.1053\/j.ackd.2019.08.004_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.2040-1124.2010.00014.x","article-title":"Sulfonylurea action re-revisited","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.004_bib64","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI25495","article-title":"ATP-sensitive potassium channelopathies: focus on insulin secretion","volume":"115","author":"Ashcroft","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.chembiol.2010.12.007","article-title":"Direct activation of epac by sulfonylurea is isoform selective","volume":"18","author":"Herbst","year":"2011","journal-title":"Chem Biol"},{"issue":"5940","key":"10.1053\/j.ackd.2019.08.004_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.1172256","article-title":"The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs","volume":"325","author":"Zhang","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1042\/BST20110640","article-title":"Epac2: a sulfonylurea receptor?","volume":"40","author":"Rehmann","year":"2012","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"issue":"14","key":"10.1053\/j.ackd.2019.08.004_bib69","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"issue":"23","key":"10.1053\/j.ackd.2019.08.004_bib70","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib71","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2337\/dc07-0339","article-title":"Counterpoint: a diabetes outcome progression trial (ADOPT): good for sulfonylureas?","volume":"30","author":"Al-Ozairi","year":"2007","journal-title":"Diabetes Care"},{"issue":"9131","key":"10.1053\/j.ackd.2019.08.004_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in\u00a0patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1053\/j.ackd.2019.08.004_bib73","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib74","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/diacare.26.4.1176","article-title":"Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use","volume":"26","author":"Leese","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib75","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0889-8529(05)70221-8","article-title":"ORAL THERAPIES FOR DIABETIC HYPERGLYCEMIA","volume":"30","author":"Lebovitz","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib77","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","article-title":"A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin","volume":"30","author":"Gangji","year":"2007","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1053\/j.ackd.2019.08.004_bib78","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib79","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","article-title":"Systematic review: glucose control and cardiovascular disease in type 2 diabetes","volume":"151","author":"Kelly","year":"2009","journal-title":"Ann Intern Med"},{"issue":"jul29 3","key":"10.1053\/j.ackd.2019.08.004_bib80","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ"},{"issue":"12","key":"10.1053\/j.ackd.2019.08.004_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11892-017-0954-4","article-title":"The infamous, famous sulfonylureas and cardiovascular safety: much ado about nothing?","volume":"17","author":"Pop","year":"2017","journal-title":"Curr Diab Rep"},{"issue":"Suppl","key":"10.1053\/j.ackd.2019.08.004_bib82","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2019.08.004_bib83","first-page":"65","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy","volume":"24","year":"1975","journal-title":"Diabetes"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib84","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/euhj.1998.1242","article-title":"Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide","volume":"20","author":"Klepzig","year":"1999","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1053\/j.ackd.2019.08.004_bib86","doi-asserted-by":"crossref","first-page":"e7638","DOI":"10.1097\/MD.0000000000007638","article-title":"Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib87","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.004_bib88","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","year":"2011","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.004_bib89","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jvs.2009.02.026","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"49","author":"Duckworth","year":"2009","journal-title":"J Vasc Surg"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.004_bib90","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/dom.12126","article-title":"Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?","volume":"15","author":"Nagendran","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib91","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/diacare.27.1.201","article-title":"Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66","volume":"27","author":"Stevens","year":"2003","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.004_bib92","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.12116","article-title":"Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ackd.2019.08.004_bib93","unstructured":"Rosenstock J, Marx N, Kahn SE, et\u00a0al. CAROLINA\u00ae: cardiovascular safety and renal microvascular outcome with linagliptin in patients with T2D at high vascular risk. Oral presentation at the 79th Scientific Sessions of the American Diabetes Association (ADA), Monday, 10 June 2019, 16:30-18:30, San Francisco, CA, USA."},{"key":"10.1053\/j.ackd.2019.08.004_bib94","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2018.03.041","article-title":"Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"151","author":"Li","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1053\/j.ackd.2019.08.004_bib95","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.12295","article-title":"Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment","volume":"16","author":"Davis","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib96","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0065-1281(11)80085-1","article-title":"Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney","volume":"92","author":"Kettmann","year":"1992","journal-title":"Acta Histochem"},{"key":"10.1053\/j.ackd.2019.08.004_bib97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0065-1281(11)80302-8","article-title":"Demonstration of glomerular DPP IV activity in kidney diseases","volume":"91","author":"Stiller","year":"1991","journal-title":"Acta Histochem"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.004_bib98","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/HYPERTENSIONAHA.112.196501","article-title":"Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells","volume":"60","author":"Jackson","year":"2012","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2019.08.004_bib99","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1053\/j.ackd.2019.08.004_bib100","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1053\/j.ackd.2019.08.004_bib101","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FJC.0000000000000258","article-title":"Diuretic and natriuretic effects of dipeptidyl peptidase-4 inhibitor teneligliptin: the contribution of glucagon-like peptide-1","volume":"66","author":"Moroi","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.ackd.2019.08.004_bib102","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.kint.2016.06.012","article-title":"Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy","volume":"90","author":"Takashima","year":"2016","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2019.08.004_bib103","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.111.186866","article-title":"Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats","volume":"340","author":"Liu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.ackd.2019.08.004_bib104","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1097\/HJH.0000000000000328","article-title":"Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy","volume":"32","author":"Sharkovska","year":"2014","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2019.08.004_bib105","doi-asserted-by":"crossref","first-page":"162092","DOI":"10.1155\/2011\/162092","article-title":"Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes(Zucker diabetic fatty rat)","volume":"2011","author":"Mega","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"10.1053\/j.ackd.2019.08.004_bib106","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.04.055","article-title":"Gemigliptin improves renal function and attenuates podocyte injury in mice with diabeticnephropathy","volume":"761","author":"Jung","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.ackd.2019.08.004_bib107","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.ackd.2019.08.004_bib110","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib111","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.004_bib112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2019.08.004_bib113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib114","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc15-1707","article-title":"Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes","volume":"40","author":"Tkac","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2019.08.004_bib115","first-page":"48","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials Diabetes","volume":"43","author":"Rehman","year":"2017","journal-title":"Metab"},{"key":"10.1053\/j.ackd.2019.08.004_bib116","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association between incretin-based drugs and the risk of acute pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib117","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.004_bib118","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities","volume":"25","author":"Lund","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.ackd.2019.08.004_bib121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.004_bib122","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2019.08.004_bib123","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib124","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1053\/j.ackd.2019.08.004_bib126","article-title":"Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL)","volume":"67","author":"Bethel","year":"2018","journal-title":"Diabetes Jul"},{"issue":"10193","key":"10.1053\/j.ackd.2019.08.004_bib127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.004_bib128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1573399813666170816142351","article-title":"Benefits of SGLT2 inhibitors beyond glycemic control \u2013 a focus on metabolic, cardiovascular and renal outcomes","volume":"14","author":"Minze","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1053\/j.ackd.2019.08.004_bib129","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ackd.2019.08.004_bib130","series-title":"Farxiga (dapagliflozin) [prescribing information]","year":"2019"},{"key":"10.1053\/j.ackd.2019.08.004_bib131","series-title":"Jardiance (empagliflozin) [prescribing information]","year":"2018"},{"key":"10.1053\/j.ackd.2019.08.004_bib132","series-title":"Steglatro (ertugliflozin) (prescribing information)","year":"2017"},{"key":"10.1053\/j.ackd.2019.08.004_bib133","series-title":"Invokana (canagliflozin) [prescribing information]","year":"2018"},{"key":"10.1053\/j.ackd.2019.08.004_bib134","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.ackd.2019.08.004_bib135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib136","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib137","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ackd.2019.08.004_bib138","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.004_bib139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabet Therap"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:01Z","timestamp":1761548521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1548559519301442"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.004","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of Metformin and Hypoglycemic Therapies","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}